These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34267079)

  • 1. Next generation epigenetic modulators to target myeloid neoplasms.
    Sasca D; Guezguez B; Kühn MWM
    Curr Opin Hematol; 2021 Sep; 28(5):356-363. PubMed ID: 34267079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic deregulation in myeloid malignancies.
    Huang HT; Figueroa ME
    Blood; 2021 Aug; 138(8):613-624. PubMed ID: 34436526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.
    Sapienza MR; Abate F; Melle F; Orecchioni S; Fuligni F; Etebari M; Tabanelli V; Laginestra MA; Pileri A; Motta G; Rossi M; Agostinelli C; Sabattini E; Pimpinelli N; Truni M; Falini B; Cerroni L; Talarico G; Piccioni R; Amente S; Indio V; Tarantino G; Brundu F; Paulli M; Berti E; Facchetti F; Dellino GI; Bertolini F; Tripodo C; Rabadan R; Pileri SA
    Haematologica; 2019 Apr; 104(4):729-737. PubMed ID: 30381297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
    Ungerstedt JS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epigenetic therapy for hematologic malignancies].
    Kobayashi Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
    Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
    Front Immunol; 2020; 11():604142. PubMed ID: 33329600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
    O'Sullivan JM; Harrison CN
    Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
    Dupéré-Richer D; Licht JD
    Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of myeloproliferative neoplasms.
    Skoda RC; Duek A; Grisouard J
    Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
    Zhao A; Zhou H; Yang J; Li M; Niu T
    Signal Transduct Target Ther; 2023 Feb; 8(1):71. PubMed ID: 36797244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surmounting cancer drug resistance: New insights from the perspective of N
    Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
    Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on the epigenome in the myeloproliferative neoplasms.
    Kim E; Abdel-Wahab O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms.
    Chen NC; Borthakur G; Pemmaraju N
    Leuk Lymphoma; 2021 Mar; 62(3):528-537. PubMed ID: 33161793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epigenetics in hematological disorders].
    Furukawa Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
    [No Abstract]   [Full Text] [Related]  

  • 17. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
    Strauss J; Figg WD
    Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in epigenetic regulators in myelodysplastic syndromes.
    Nikoloski G; van der Reijden BA; Jansen JH
    Int J Hematol; 2012 Jan; 95(1):8-16. PubMed ID: 22234528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
    Morel D; Almouzni G; Soria JC; Postel-Vinay S
    Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.